Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Free Report) have received an average rating of “Buy” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month price objective among brokerages that have covered the stock in the last year is $68.50.
Several brokerages have commented on SWTX. Wedbush reissued an “outperform” rating and issued a $77.00 price target (up previously from $75.00) on shares of SpringWorks Therapeutics in a research report on Wednesday, August 28th. HC Wainwright reissued a “buy” rating and set a $76.00 target price on shares of SpringWorks Therapeutics in a research note on Wednesday, August 28th. Finally, JPMorgan Chase & Co. increased their price target on SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th.
Get Our Latest Research Report on SWTX
Institutional Investors Weigh In On SpringWorks Therapeutics
SpringWorks Therapeutics Trading Down 1.2 %
Shares of NASDAQ SWTX opened at $30.12 on Friday. The stock has a market capitalization of $2.23 billion, a PE ratio of -5.86 and a beta of 0.78. SpringWorks Therapeutics has a twelve month low of $18.00 and a twelve month high of $53.92. The stock has a fifty day simple moving average of $36.00 and a 200-day simple moving average of $39.00.
SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.12) by $0.58. The business had revenue of $59.73 million for the quarter, compared to analyst estimates of $34.42 million. The firm’s revenue for the quarter was up 59732900.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.25) EPS. On average, equities analysts predict that SpringWorks Therapeutics will post -3.36 earnings per share for the current year.
SpringWorks Therapeutics Company Profile
SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
See Also
- Five stocks we like better than SpringWorks Therapeutics
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- CD Calculator: Certificate of Deposit Calculator
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- What is a Special Dividend?
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.